Pegylated liposomal doxorubicin in the management of ovarian cancer

References

• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893 - 917; http://dx.doi.org/10.1002/ijc.25516; PMID: 21351269
   PubMed Web of Science ®Google Scholar
• Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62:220 - 41; http://dx.doi.org/10.3322/caac.21149; PMID: 22700443
   PubMed Web of Science ®Google Scholar
• Thigpen T, duBois A, McAlpine J, DiSaia P, Fujiwara K, Hoskins W, Kristensen G, Mannel R, Markman M, Pfisterer J, et al, Gynecologic Cancer InterGroup. First-line therapy in ovarian cancer trials. Int J Gynecol Cancer 2011; 21:756 - 62; http://dx.doi.org/10.1097/IGC.0b013e31821ce75d; PMID: 21543937
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21:3194 - 200; http://dx.doi.org/10.1200/JCO.2003.02.153; PMID: 12860964
   PubMed Web of Science ®Google Scholar
• Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB, Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004; 96:1682 - 91; http://dx.doi.org/10.1093/jnci/djh323; PMID: 15547181
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, et al, Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365:2473 - 83; http://dx.doi.org/10.1056/NEJMoa1104390; PMID: 22204724
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, et al, ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365:2484 - 96; http://dx.doi.org/10.1056/NEJMoa1103799; PMID: 22204725
   PubMed Web of Science ®Google Scholar
• Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S, Sessa C, Castiglione M, ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21:Suppl 5 v23 - 30; http://dx.doi.org/10.1093/annonc/mdq244; PMID: 20555088
   PubMed Web of Science ®Google Scholar
• Cristea M, Han E, Salmon L, Morgan RJ. Practical considerations in ovarian cancer chemotherapy. Ther Adv Med Oncol 2010; 2:175 - 87; http://dx.doi.org/10.1177/1758834010361333; PMID: 21789133
   PubMedGoogle Scholar
• Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade-Lauraine E, Sehouli J, et al, Gynecologic Cancer InterGroup. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer 2011; 21:771 - 5; http://dx.doi.org/10.1097/IGC.0b013e31821bb8aa; PMID: 21543939
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010; 28:3323 - 9; http://dx.doi.org/10.1200/JCO.2009.25.7519; PMID: 20498395
   PubMed Web of Science ®Google Scholar
• Weber B, Lortholary A, Mayer F, Bourgeois H, Orfeuvre H, Combe M, Platini C, Cretin J, Fric D, Paraiso D, et al. Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial. Anticancer Res 2009; 29:4195 - 200; PMID: 19846972
   PubMed Web of Science ®Google Scholar
• Ferrero JM, Weber B, Geay JF, Lepille D, Orfeuvre H, Combe M, Mayer F, Leduc B, Bourgeois H, Paraiso D, et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 2007; 18:263 - 8; http://dx.doi.org/10.1093/annonc/mdl376; PMID: 17108151
   PubMed Web of Science ®Google Scholar
• Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, Pujade-Lauraine E, Reed N, Lorusso D, Siena S, et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Ann Oncol 2012; 23:1185 - 9; http://dx.doi.org/10.1093/annonc/mdr441; PMID: 21976386
   PubMed Web of Science ®Google Scholar
• Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecol Oncol 2004; 94:67 - 73; http://dx.doi.org/10.1016/j.ygyno.2004.03.047; PMID: 15262121
   PubMed Web of Science ®Google Scholar
• Kavanagh J, Tresukosol D, Edwards C, Freedman R, Gonzalez de Leon C, Fishman A, Mante R, Hord M, Kudelka A. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 1995; 13:1584 - 8; PMID: 7602347
   PubMed Web of Science ®Google Scholar
• Pignata S, Lauraine EP, du Bois A, Pisano C. Pegylated liposomal doxorubicin combined with carboplatin: a rational treatment choice for advanced ovarian cancer. Crit Rev Oncol Hematol 2010; 73:23 - 30; http://dx.doi.org/10.1016/j.critrevonc.2009.08.004; PMID: 19782576
   PubMed Web of Science ®Google Scholar
• Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010; 28:3107 - 14; http://dx.doi.org/10.1200/JCO.2009.25.4037; PMID: 20516432
   PubMed Web of Science ®Google Scholar
• Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Kaye SB, Colombo N, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 2011; 22:39 - 48; http://dx.doi.org/10.1093/annonc/mdq352; PMID: 20643862
   PubMed Web of Science ®Google Scholar
• Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, Wang Y, Scribner DR Jr., Marciniack M, Naumann RW, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007; 25:2811 - 8; http://dx.doi.org/10.1200/JCO.2006.09.6735; PMID: 17602086
   PubMed Web of Science ®Google Scholar
• Gordon AN, Tonda M, Sun S, Rackoff W, Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004; 95:1 - 8; http://dx.doi.org/10.1016/j.ygyno.2004.07.011; PMID: 15385103
   PubMed Web of Science ®Google Scholar
• Kucukoner M, Isikdogan A, Yaman S, Gumusay O, Unal O, Ulas A, Elkiran ET, Kaplan MA, Ozdemir N, Inal A, et al. Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology. Asian Pac J Cancer Prev 2012; 13:3973 - 6; http://dx.doi.org/10.7314/APJCP.2012.13.8.3973; PMID: 23098502
   PubMed Web of Science ®Google Scholar
• Lortholary A, Largillier R, Weber B, Gladieff L, Alexandre J, Durando X, Slama B, Dauba J, Paraiso D, Pujade-Lauraine E, GINECO group France. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO). Ann Oncol 2012; 23:346 - 52; http://dx.doi.org/10.1093/annonc/mdr149; PMID: 21562072
   PubMed Web of Science ®Google Scholar
• Chiyoda T, Tsuda H, Nomura H, Kataoka F, Tominaga E, Suzuki A, Susumu N, Aoki D. Effects of third-line chemotherapy for women with recurrent ovarian cancer who received platinum/taxane regimens as first-line chemotherapy. Eur J Gynaecol Oncol 2010; 31:364 - 8; PMID: 20882873
   PubMed Web of Science ®Google Scholar
• Seliger G, Mueller LP, Kegel T, Kantelhardt EJ, Grothey A, Groe R, Strauss HG, Koelbl H, Thomssen C, Schmoll HJ. Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer. Int J Gynecol Cancer 2009; 19:1446 - 53; http://dx.doi.org/10.1111/IGC.0b013e3181b62f38; PMID: 20009905
   PubMed Web of Science ®Google Scholar
• Bamias A, Bamia C, Zagouri F, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, et al. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents. Oncology 2013; 84:158 - 65; http://dx.doi.org/10.1159/000341366; PMID: 23296063
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Corrado G, Licameli A, Lorusso D, Fuoco G, Pisconti S, Scambia G. Pegylated liposomal doxorubicin in the management of ovarian cancer. 2010; 6:463 - 83
   Google Scholar
• Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, Del Medico P, Scaltriti L, Katsaros D, Priolo D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008; 26:890 - 6; http://dx.doi.org/10.1200/JCO.2007.13.6606; PMID: 18281662
   PubMed Web of Science ®Google Scholar
• Cannistra SA. Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?. J Clin Oncol 2010; 28:3101 - 3; http://dx.doi.org/10.1200/JCO.2010.29.7077; PMID: 20516442
   PubMed Web of Science ®Google Scholar
• Muggia FM. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs 1997; 54:Suppl 4 22 - 9; http://dx.doi.org/10.2165/00003495-199700544-00006; PMID: 9361958
   PubMed Web of Science ®Google Scholar
• Alberts DS, Garcia DJ. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997; 54:Suppl 4 30 - 5; http://dx.doi.org/10.2165/00003495-199700544-00007; PMID: 9361959
   PubMed Web of Science ®Google Scholar
• Baumann KH, Wagner U, du Bois A. The changing landscape of therapeutic strategies for recurrent ovarian cancer. Future Oncol 2012; 8:1135 - 47; http://dx.doi.org/10.2217/fon.12.112; PMID: 23030488
   PubMed Web of Science ®Google Scholar
• Staropoli N, Ciliberto D, Botta C, Fiorillo L, Gualtieri S, Salvino A, Tassone P, Tagliaferri P. A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?. J Ovarian Res 2013; 6:10; http://dx.doi.org/10.1186/1757-2215-6-10; PMID: 23388584
   PubMedGoogle Scholar
• Dear RF, Gao B, Harnett P. Recurrent ovarian cancer: treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience. Asia Pac J Clin Oncol 2010; 6:66 - 73; http://dx.doi.org/10.1111/j.1743-7563.2009.01263.x; PMID: 20398040
   PubMed Web of Science ®Google Scholar
• Vergote I, Finkler N, del Campo J, Lohr A, Hunter J, Matei D, Kavanagh J, Vermorken JB, Meng L, Jones M, et al, ASSIST-1 Study Group. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer 2009; 45:2324 - 32; http://dx.doi.org/10.1016/j.ejca.2009.05.016; PMID: 19515553
   PubMed Web of Science ®Google Scholar
• Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19:3312 - 22; PMID: 11454878
   PubMed Web of Science ®Google Scholar
• Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM Jr., Michelin DP, Lanzotti VJ, Anderson GL, Alberts DS. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol 2010; 116:323 - 5; http://dx.doi.org/10.1016/j.ygyno.2009.11.026; PMID: 20044128
   PubMed Web of Science ®Google Scholar
• Sehouli J, Meier W, Wimberger P, Chekerov R, Belau A, Mahner S, Kurzeder C, Hilpert F, Klare P, Doerfel S, et al. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabin plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A randomized phase III trial of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG intergroup study (HECTOR). ASCO Meeting Abstracts 2012; 30:5031.
   Google Scholar
• Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, Gebbia V, Musso P, Frigerio L, Del Medico P, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol 2011; 29:3628 - 35; http://dx.doi.org/10.1200/JCO.2010.33.8566; PMID: 21844495
   PubMed Web of Science ®Google Scholar
• Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009; 27:1419 - 25; http://dx.doi.org/10.1200/JCO.2008.19.1684; PMID: 19224846
   PubMed Web of Science ®Google Scholar
• Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, Amnon A, Bell-McGuinn KM, Chen LM, Friedlander M, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012; 30:372 - 9; http://dx.doi.org/10.1200/JCO.2011.36.9215; PMID: 22203755
   PubMed Web of Science ®Google Scholar
• Vergote I, Finkler NJ, Hall JB, Melnyk O, Edwards RP, Jones M, Keck JG, Meng L, Brown GL, Rankin EM, et al. Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer. Int J Gynecol Cancer 2010; 20:772 - 80; http://dx.doi.org/10.1111/IGC.0b013e3181daaf59; PMID: 20973267
   PubMed Web of Science ®Google Scholar
• Alberts DS, Liu PY, Wilczynski SP, Clouser MC, Lopez AM, Michelin DP, Lanzotti VJ, Markman M, Southwest Oncology Group. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol 2008; 108:90 - 4; http://dx.doi.org/10.1016/j.ygyno.2007.08.075; PMID: 17949799
   PubMed Web of Science ®Google Scholar
• Bafaloukos D, Linardou H, Aravantinos G, Papadimitriou C, Bamias A, Fountzilas G, Kalofonos HP, Kosmidis P, Timotheadou E, Makatsoris T, et al. A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. BMC Med 2010; 8:3; http://dx.doi.org/10.1186/1741-7015-8-3; PMID: 20055981
   PubMed Web of Science ®Google Scholar
• Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, Scambia G, Engelholm SA, Joly F, Weber D, et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol 2012; 30:3841 - 7; http://dx.doi.org/10.1200/JCO.2011.38.8082; PMID: 22987083
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote IB, Witteveen P, Bamias A, et al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). ASCO Meeting Abstracts 2012; 30:LBA5002.
   Google Scholar
• Rose P, Edwards R, Finkler N, Seiden M, Duska L, Krasner C, Cappuccini F, Kolevska T, Brand E, Brown G, et al. Phase 3 Study: Canfosfamide (C, TLK286) plus carboplatin (P) vs liposomal doxorubicin (D) as 2nd line therapy of platinum (P) resistant ovarian cancer (OC). ASCO Meeting Abstracts 2007; 25:LBA5529.
   Google Scholar
• O'Byrne KJ. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer. Proc Am Soc Clin Oncol 2002; 21:203a
   Google Scholar
• Armijo-Olivo S, Stiles CR, Hagen NA, Biondo PD, Cummings GG. Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research. J Eval Clin Pract 2012; 18:12 - 8; http://dx.doi.org/10.1111/j.1365-2753.2010.01516.x; PMID: 20698919
   PubMed Web of Science ®Google Scholar
• Detsky AS, Naylor CD, O’Rourke K, McGeer AJ, L’Abbé KA. Incorporating variations in the quality of individual randomized trials into metaanalysis. J Clin Epidemiol 1992; 45:255 - 65; http://dx.doi.org/10.1016/0895-4356(92)90085-2; PMID: 1569422
   PubMed Web of Science ®Google Scholar
• Lawrie TA, Rabbie R, Thoma C, Morrison J. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer. Cochrane Database Syst Rev 2013; 10:CD010482; PMID: 24142521
   PubMedGoogle Scholar
• Lawrie TA, Bryant A, Cameron A, Gray E, Morrison J. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database Syst Rev 2013; 7:CD006910; PMID: 23835762
   PubMed Web of Science ®Google Scholar
• Gibson JM, Alzghari S, Ahn C, Trantham H, La-Beck NM. The role of pegylated liposomal doxorubicin in ovarian cancer: a metaanalysis of randomized clinical trials. Oncologist 2013; 18:1022 - 31; http://dx.doi.org/10.1634/theoncologist.2013-0126; PMID: 23881990
   PubMed Web of Science ®Google Scholar
• Mäenpää J. [First-line bevacizumab in ovarian cancer]. Duodecim 2011; 127:2037 - 44; PMID: 22073535
   PubMedGoogle Scholar
• Brundage M, Gropp M, Mefti F, Mann K, Lund B, Gebski V, Wolfram G, Reed N, Pignata S, Ferrero A, et al. Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial. Ann Oncol 2012; 23:2020 - 7; http://dx.doi.org/10.1093/annonc/mdr583; PMID: 22291207
   PubMed Web of Science ®Google Scholar
• Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, et al, ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361:2099 - 106; http://dx.doi.org/10.1016/S0140-6736(03)13718-X; PMID: 12826431
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30:2039 - 45; http://dx.doi.org/10.1200/JCO.2012.42.0505; PMID: 22529265
   PubMed Web of Science ®Google Scholar
• Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Park YC, Parekh TV, Poveda AM. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer 2012; 48:2361 - 8; http://dx.doi.org/10.1016/j.ejca.2012.04.001; PMID: 22541893
   PubMed Web of Science ®Google Scholar
• Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25:5180 - 6; http://dx.doi.org/10.1200/JCO.2007.12.0782; PMID: 18024865
   PubMed Web of Science ®Google Scholar
• Ciliberto D, Botta C, Correale P, Rossi M, Caraglia M, Tassone P, Tagliaferri P. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a metaanalysis of randomised trials. Eur J Cancer 2013; 49:593 - 603; http://dx.doi.org/10.1016/j.ejca.2012.08.019; PMID: 22989511
   PubMed Web of Science ®Google Scholar
• Ciliberto D, Prati U, Roveda L, Barbieri V, Staropoli N, Abbruzzese A, Caraglia M, Di Maio M, Flotta D, Tassone P, et al. Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and metaanalysis of randomized controlled trials. Oncol Rep 2012; 27:1849 - 56; PMID: 22446591
   PubMed Web of Science ®Google Scholar
• Stewart LA, Parmar MK, Tierney JF. Metaanalyses and large randomized, controlled trials. N Engl J Med 1998; 338:61 - , author reply 61-2; PMID: 9424569
   PubMed Web of Science ®Google Scholar
• Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform metaanalyses of the published literature for survival endpoints. Stat Med 1998; 17:2815 - 34; http://dx.doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; PMID: 9921604
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62:e1 - 34; http://dx.doi.org/10.1016/j.jclinepi.2009.06.006; PMID: 19631507
   PubMedGoogle Scholar
• Crowther M, Lim W, Crowther MA. Systematic review and metaanalysis methodology. Blood 2010; 116:3140 - 6; http://dx.doi.org/10.1182/blood-2010-05-280883; PMID: 20656933
   PubMed Web of Science ®Google Scholar
• Wang D, Mou ZY, Zhai JX, Zong HX, Zhao XD. [Application of Stata software to test heterogeneity in metaanalysis method]. Zhonghua Liu Xing Bing Xue Za Zhi 2008; 29:726 - 9; PMID: 19031771
   PubMedGoogle Scholar
• DerSimonian R, Levine RJ. Resolving discrepancies between a metaanalysis and a subsequent large controlled trial. JAMA 1999; 282:664 - 70; http://dx.doi.org/10.1001/jama.282.7.664; PMID: 10517720
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Kacker R. Random-effects model for metaanalysis of clinical trials: an update. Contemp Clin Trials 2007; 28:105 - 14; http://dx.doi.org/10.1016/j.cct.2006.04.004; PMID: 16807131
   PubMed Web of Science ®Google Scholar
• Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, Rücker G, Harbord RM, Schmid CH, et al. Recommendations for examining and interpreting funnel plot asymmetry in metaanalyses of randomised controlled trials. BMJ 2011; 343:d4002; http://dx.doi.org/10.1136/bmj.d4002; PMID: 21784880
   PubMed Web of Science ®Google Scholar
• Boston RC, Sumner AE. STATA: a statistical analysis system for examining biomedical data. Adv Exp Med Biol 2003; 537:353 - 69; http://dx.doi.org/10.1007/978-1-4419-9019-8_23; PMID: 14995047
   PubMed Web of Science ®Google Scholar